Activity of Raloxifene in Immature and Ovariectomized Rat Uterotrophic Assays

This publication has 14 references indexed in Scilit:

• Editorial: Estrogens from Plastic--Are We Being Exposed?
  Endocrinology, 1997
• The Rodent Uterotrophic Assay: Critical Protocol Features, Studies with Nonyl Phenols, and Comparison with a Yeast Estrogenicity Assay
  Regulatory Toxicology and Pharmacology, 1997
• Survey and Assessment of Mammalian Estrogen Biological Assays for Hazard Characterization
  Fundamental and Applied Toxicology, 1996
• Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia
  Endocrinology, 1996
• Anin VivoBattery for Identifying Endocrine Modulators That Are Estrogenic or Dopamine Regulators
  Fundamental and Applied Toxicology, 1996
• Drug's Link to Genes Reveals Estrogen's Many Sides
  Science, 1996
• Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop.
  Environmental Health Perspectives, 1996
• Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
  Journal of Clinical Investigation, 1994
• Developmental effects of endocrine-disrupting chemicals in wildlife and humans.
  Environmental Health Perspectives, 1993
• Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (LY 156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity
  Journal of Medicinal Chemistry, 1984